The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review

Chelation Therapy

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Chelation Therapy


High impact information on Chelation Therapy


Chemical compound and disease context of Chelation Therapy


Biological context of Chelation Therapy


Anatomical context of Chelation Therapy


Associations of Chelation Therapy with chemical compounds

  • This study was designed to determine whether chelation therapy with deferoxamine before the age of puberty would ameliorate this problem [26].
  • INTERVENTIONS: Patients were randomly assigned to receive infusion with either weight-adjusted (40 mg/kg) EDTA chelation therapy (n = 41) or placebo (n = 43) for 3 hours per treatment, twice weekly for 15 weeks and once per month for an additional 3 months [3].
  • The child was treated with chelation therapy with D-penicillamine [27].
  • Anaemia and aluminium chelation therapy in dialysis patients [28].
  • At autopsy, an increased bone lead content was documented, suggesting that the edetic acid lead mobilization test may underestimate total body lead stores and that chelation therapy may not be effective in reversing advanced lead nephropathy [29].

Gene context of Chelation Therapy


Analytical, diagnostic and therapeutic context of Chelation Therapy


  1. Iron-chelation therapy with oral deferipronein patients with thalassemia major. Olivieri, N.F., Brittenham, G.M., Matsui, D., Berkovitch, M., Blendis, L.M., Cameron, R.G., McClelland, R.A., Liu, P.P., Templeton, D.M., Koren, G. N. Engl. J. Med. (1995) [Pubmed]
  2. Effect of iron chelation therapy on recovery from deep coma in children with cerebral malaria. Gordeuk, V., Thuma, P., Brittenham, G., McLaren, C., Parry, D., Backenstose, A., Biemba, G., Msiska, R., Holmes, L., McKinley, E. N. Engl. J. Med. (1992) [Pubmed]
  3. Chelation therapy for ischemic heart disease: a randomized controlled trial. Knudtson, M.L., Wyse, D.G., Galbraith, P.D., Brant, R., Hildebrand, K., Paterson, D., Richardson, D., Burkart, C., Burgess, E. JAMA (2002) [Pubmed]
  4. Chelation therapy for intermittent claudication. A double-blind, randomized, controlled trial. van Rij, A.M., Solomon, C., Packer, S.G., Hopkins, W.G. Circulation (1994) [Pubmed]
  5. Heart failure in beta-thalassemia syndromes: a decade of progress. Hahalis, G., Alexopoulos, D., Kremastinos, D.T., Zoumbos, N.C. Am. J. Med. (2005) [Pubmed]
  6. The effect of chelation therapy with succimer on neuropsychological development in children exposed to lead. Rogan, W.J., Dietrich, K.N., Ware, J.H., Dockery, D.W., Salganik, M., Radcliffe, J., Jones, R.L., Ragan, N.B., Chisolm, J.J., Rhoads, G.G. N. Engl. J. Med. (2001) [Pubmed]
  7. Insulin resistance and hyperinsulinemia in patients with thalassemia major treated by hypertransfusion. Merkel, P.A., Simonson, D.C., Amiel, S.A., Plewe, G., Sherwin, R.S., Pearson, H.A., Tamborlane, W.V. N. Engl. J. Med. (1988) [Pubmed]
  8. Chelation of cadmium with BAL and DTPA in rats. Cherian, M.G. Nature (1980) [Pubmed]
  9. Synergistic chelation therapy or mixed ligand complexes for plutonium and cadmium poisoning? May, P.M., Williams, D.R. Nature (1979) [Pubmed]
  10. Metabolism of americium-241 in man: an unusual case of internal contamination of a child and his father. Cohen, N., Sasso, T.L., Wrenn, M.E. Science (1979) [Pubmed]
  11. Role of deferiprone in chelation therapy for transfusional iron overload. Hoffbrand, A.V., Cohen, A., Hershko, C. Blood (2003) [Pubmed]
  12. Wilson's disease. Development of neurological disease after beginning penicillamine therapy. Glass, J.D., Reich, S.G., DeLong, M.R. Arch. Neurol. (1990) [Pubmed]
  13. Metal excretion and magnesium retention in patients with intermittent claudication treated with intravenous disodium EDTA. Guldager, B., Jørgensen, P.J., Grandjean, P. Clin. Chem. (1996) [Pubmed]
  14. Polymer conjugation reduces deferoxamine induced retinopathy in an albino rat model. Gehlbach, P.L., Purple, R.L., Hallaway, P.E., Hedlund, B.E. Invest. Ophthalmol. Vis. Sci. (1993) [Pubmed]
  15. Respiratory failure and death following acute inhalation of mercury vapor. A clinical and histologic perspective. Rowens, B., Guerrero-Betancourt, D., Gottlieb, C.A., Boyes, R.J., Eichenhorn, M.S. Chest (1991) [Pubmed]
  16. Aluminum and renal osteodystrophy. Nebeker, H.G., Coburn, J.W. Annu. Rev. Med. (1986) [Pubmed]
  17. Aggressive approach in the treatment of acute lead encephalopathy with an extraordinarily high concentration of lead. Gordon, R.A., Roberts, G., Amin, Z., Williams, R.H., Paloucek, F.P. Archives of pediatrics & adolescent medicine. (1998) [Pubmed]
  18. Iron toxicity and chelation therapy. Britton, R.S., Leicester, K.L., Bacon, B.R. Int. J. Hematol. (2002) [Pubmed]
  19. Elevated plasma chemokine CCL18/PARC in beta-thalassemia. Dimitriou, E., Verhoek, M., Altun, S., Karabatsos, F., Moraitou, M., Youssef, J., Boot, R., Sarafidou, J., Karagiorga, M., Aerts, H., Michelakakis, H. Blood Cells Mol. Dis. (2005) [Pubmed]
  20. The iron chelator pyridoxal isonicotinoyl hydrazone (PIH) and its analogues prevent damage to 2-deoxyribose mediated by ferric iron plus ascorbate. Hermes-Lima, M., Ponka, P., Schulman, H.M. Biochim. Biophys. Acta (2000) [Pubmed]
  21. Effect of chelation therapy on endothelial function in patients with coronary artery disease: PATCH substudy. Anderson, T.J., Hubacek, J., Wyse, D.G., Knudtson, M.L. J. Am. Coll. Cardiol. (2003) [Pubmed]
  22. Rapid removal of excessive iron with daily, high-dose intravenous chelation therapy. Cohen, A.R., Mizanin, J., Schwartz, E. J. Pediatr. (1989) [Pubmed]
  23. Deferoxamine-induced bone dysplasia in the distal femur and patella of pediatric patients and young adults: MR imaging appearance. Chan, Y., Li, C., Chu, W.C., Pang, L., Cheng, J.C., Chik, K.W. AJR. American journal of roentgenology. (2000) [Pubmed]
  24. Computer simulation of metal ion equilibria in biofluids. IV. Plutonium speciation in human blood plasma and chelation therapy using polyaminopolycarboxylic acids. Duffield, J.R., May, P.M., Williams, D.R. J. Inorg. Biochem. (1984) [Pubmed]
  25. High-dose intravenous desferrioxamine (DFO) delivery in four thalassemic patients allergic to subcutaneous DFO administration. Lombardo, T., Ferro, G., Frontini, V., Percolla, S. Am. J. Hematol. (1996) [Pubmed]
  26. Effect of age at the start of iron chelation therapy on gonadal function in beta-thalassemia major. Bronspiegel-Weintrob, N., Olivieri, N.F., Tyler, B., Andrews, D.F., Freedman, M.H., Holland, F.J. N. Engl. J. Med. (1990) [Pubmed]
  27. Diagnosis of Wilson's disease in an asymptomatic sibling by DNA linkage analysis. Maier-Dobersberger, T., Mannhalter, C., Rack, S., Granditsch, G., Kaserer, K., Korninger, L., Steindl, P., Gangl, A., Ferenci, P. Gastroenterology (1995) [Pubmed]
  28. Anaemia and aluminium chelation therapy in dialysis patients. Tielemans, C., Collart, F., Wens, R., Smeyers-Verbeeke, J., Van Hooff, I., Dratwa, M., Verbeelen, D. Lancet (1988) [Pubmed]
  29. Failure of chelation therapy in lead nephropathy. Germain, M.J., Braden, G.L., Fitzgibbons, J.P. Arch. Intern. Med. (1984) [Pubmed]
  30. Neuroendocrine effects of toxic and low blood lead levels in children. Huseman, C.A., Varma, M.M., Angle, C.R. Pediatrics (1992) [Pubmed]
  31. Hepatic computed tomography for monitoring the iron status of haemodialysis patients with haemosiderosis treated with recombinant human erythropoietin. De Marchi, S., Cecchin, E. Clin. Sci. (1991) [Pubmed]
  32. Serum neopterin, interleukin-4, and interleukin-6 concentrations in cerebral malaria patients and the effect of iron chelation therapy. Thuma, P.E., Weiss, G., Herold, M., Gordeuk, V.R. Am. J. Trop. Med. Hyg. (1996) [Pubmed]
  33. Up-regulation of vascular endothelial growth factor production by iron chelators. Beerepoot, L.V., Shima, D.T., Kuroki, M., Yeo, K.T., Voest, E.E. Cancer Res. (1996) [Pubmed]
  34. Lead, zinc, and erythrocyte delta-aminolevulinic acid dehydratase: relationships in lead toxicity. Thomasino, J.A., Zuroweste, E., Brooks, S.M., Petering, H.G., Lerner, S.I., Finelli, V.N. Arch. Environ. Health (1977) [Pubmed]
  35. Ultrafiltration studies in vitro of serum aluminum in dialysis patients after deferoxamine chelation therapy. Leung, F.Y., Hodsman, A.B., Muirhead, N., Henderson, A.R. Clin. Chem. (1985) [Pubmed]
  36. Hemosiderosis in a dialysis patient: treatment with hemofiltration and deferoxamine chelation therapy. McCarthy, J.T., Libertin, C.R., Mitchell, J.C., Fairbanks, V.F. Mayo Clin. Proc. (1982) [Pubmed]
  37. Neocytopheresis: a new approach for the transfusion of patients with thalassaemia major. Triadou, P., Girot, R., Rebibo, D., Lemau, D., Mattlinger, B., Bolo, P., Maier-Redelsperger, M., Barritault, L. Eur. J. Pediatr. (1986) [Pubmed]
  38. Removal of trace metals by continuous ambulatory peritoneal dialysis after desferrioxamine B chelation therapy. Navarro, J.A., Granadillo, V.A., Rodríguez-Iturbe, B., García, R., Salgado, O., Romero, R.A. Clin. Nephrol. (1991) [Pubmed]
  39. HFE gene mutations and iron metabolism in Wilson's disease. Erhardt, A., Hoffmann, A., Hefter, H., Häussinger, D. Liver (2002) [Pubmed]
WikiGenes - Universities